Cannabinoid pharmaceuticals now in development for inflammatory bowel
disease and narcotic bowel syndrome, a severe form of opiate-induced abdominal
pain
LOS ANGELES, CA – (February 1, 2017) — Vitality
Biopharma, Inc. (OTCQB: VBIO) (“Vitality Biopharma”, “Vitality”, or
the “Company”) a corporation dedicated to the development of cannabinoid
prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the
treatment of serious neurological and inflammatory disorders, today announced
the publication of a scientific manuscript that details internal research
efforts including the discovery and production of cannabinoid glycosides.
The scientific manuscript is titled, “Cannabinoid glycosides: In
vitro production of a new class of cannabinoids with improved
physicochemical properties,” which details the scientific pathway undertaken by
the Company’s research and development team towards the discovery of a
multifunctional plant enzyme from Stevia rebaudiana, as well as an
ability to produce a diverse class of cannabinoid compounds known as
cannabinoid glycosides, or cannabosides. The manuscript has been
published through bioRxiv’s Biochemistry section on New Results, which focuses
on advances in life sciences research. The full manuscript can be found here: http://biorxiv.org/content/early/2017/01/30/104349.
Small molecule glycosylation is increasingly recognized within the
pharmaceutical and biotechnology industries as a reliable means to alter the
solubility and stability of drug compounds. Glycosylation may enable
prodrug development strategies that extend patent life, improve the bioavailability
of existing medications, and reduce side effects through targeted drug
delivery.
Traditionally, most pharmaceutical companies employ chemical synthesis
methods, but chemical glycosylation is often ineffective due to the need for
complex multistep synthetic routes that deliver inadequate yields. In
2013, Vitality Biopharma initiated a research program to overcome this key
hurdle, and developed efficient means of glycosylation through enzymatic
biosynthesis. In late 2015 and 2016, Vitality scientists applied this
technology towards cannabinoids, including cannabidiol (CBD) and
tetrahydrocannabinol (THC), creating a new class of cannabinoid glycosides
called “cannabosides.”
Vitality has already filed for intellectual property covering the
subject matter described in this work, including composition of matter claims
for more than 20 cannabinoid glycoside compounds. Cannabosides are now
being developed as pharmaceuticals for the treatment of inflammatory bowel
disease and narcotic bowel syndrome, a severe form of opiate-induced abdominal
pain.
About Vitality Biopharma (OTCQB: VBIO)
Vitality Biopharma is dedicated to unlocking the power of cannabinoids
for the treatment of serious neurological and inflammatory disorders. For more
information, visit: www.vitality.bio.
Follow us on Facebook, Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is
defined in Section 27(a) of the United States Securities Act of 1933, as
amended and Section 21(e) of the Securities Exchange Act of 1934, as amended.
Statements in this press release which are not purely historical are
forward-looking statements and include any statements regarding beliefs, plans,
expectations or intentions regarding the future. Such factors include, among
others, the inherent uncertainties associated with new projects and development
stage companies. These forward-looking statements are made as of the date of
this news release, and we assume no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ from those
projected in the forward-looking statements. Although we believe that any
beliefs, plans, expectations and intentions contained in this press release are
reasonable, there can be no assurance that any such beliefs, plans,
expectations or intentions will prove to be accurate. Investors should consult
all of the information set forth herein and should also refer to the risk
factors disclosure outlined in our annual report on Form 10-K for the most
recent fiscal year, our quarterly reports on Form 10-Q and other periodic
reports filed from time-to-time with the Securities and Exchange Commission.
Resources: http://vitality.bio/2017/02/vitality-biopharma-publishes-scientific-data-discovery-cannabinoid-glycosides/